Cholesterol and its esters in the bile of rats in tetracyclineinduced hepatosis and under the using of milk phospholipids

TitleCholesterol and its esters in the bile of rats in tetracyclineinduced hepatosis and under the using of milk phospholipids
Publication TypeJournal Article
Year of Publication2020
AuthorsTomchuk, VA, Gryshchenko, VA, Veselsky, SP, Reshetnik, YM
Abbreviated Key TitleDopov. Nac. akad. nauk Ukr.
DOI10.15407/dopovidi2020.12.093
Issue12
SectionBiology
Pagination93-99
Date Published12/2020
LanguageUkrainian
Abstract

The increase of disorders of the cholesterol metabolism and the bile formation determines the need of the search for possible substances correcting the cholesterol metabolism in the liver. It is found that, in laboratory rats with an experimental drug form of steatosis, the excretion of cholesterol and, especially, cholesterol esters to the bile ducts is inhibited, and their ratio in bile is significantly impaired. The use of bioadditive “FLP-MD” made on milk phospholipids has a corrective effect on the concentration of cholesterol and its esters in bile of rats with tetracycline-induced steatosis. This allows us to recommend bioadditive “FLP-MD” made on milk phospholipids to improve the cholesterol metabolism in patients with clinical cases of drug-induced liver damage.

Keywordsbile, cholesterol, cholesterol’s esters, milk phospholipids, rats, steatosis, tetracycline
References: 

1. Zhang, Q.-Q. & Lu, L.-G. (2015). Nonalcoholic fatty liver disease: dyslipidemia, risk for cardiovascular complications, and treatment strategy. J. Clin. Transl. Hepatol., 3, No. 1, pp. 78-84. https://doi.org/10.14218/JCTH.2014.00037
2. Wang, Y., Ding, W.-X. & Li, T. (2019). Cholesterol and bile acid-mediated regulation of autophagy in fatty liver diseases and atherosclerosis. Biochim. Biophys. Acta., 1863, No. 7, pp. 726-733. https://doi.org/10.1016/j.bbalip.2018.04.005
3. Püschel, G.P. & Henkel, J. (2018). Dietary cholesterol does not break your heart but kills your liver. Porto Biomed. J., 3, No. 1, e12. https://doi.org/10.1016/j. pbj.0000000000000012
4. Kaiser, T., Kinny-Köster, B., Bartels, M., Berg, T., Scholz, M., Engelmann, C., Seehofer, D., Becker, S., Ceglarek, U. & Thiery, J. (2017). Cholesterol esterification in plasma as a biomarker for liver function and prediction of mortality. BMC Gastroenterol., 17, No. 1, 57. https://doi.org/10.1186/s12876-017-0614-9
5. Dikkers, A. & Tietge, U.J.F. (2010). Biliary cholesterol secretion: More than a simple ABC. World J. Gastroenterol., 16, No. 47, pp. 5936-5945. https://doi.org/10.3748/wjg.v16.i47.5936
6. Rudling, M., Laskar, A. & Straniero, S. (2019). Gallbladder bile supersaturated with cholesterol in gallstone patients preferentially develops from shortage of bile acids. J. Lipid Res., 60, No. 3, pp. 498-505. https://doi.org/10.1194/jlr.S091199
7. Gryshchenko, V. A. (2019). Blood and acid composition of blood and biles in calves at enteropatology and application of milk phospholipids. Ukr. J. Vet. Sci., 10, No. 4, pp. 36-42 (in Ukranian). https://doi.org/10.31548/ujvs2019.04.005
8. Varganova, D. L., Pavlov, C. S., Casazza, G., Nikolova, D. & Gluud, C. (2019). Essential phospholipids for people with non-alcoholic fatty liver disease. Cochrane Database Syst Rev., No. 4, CD013301. https://doi.org/10.1002/14651858.CD013301
9. Maev, I. V., Samsonov, A. A., Palgova, L. K., Pavlov, C. S., Shirokova, E. N., Vovk, E. I. & Starostin, K. M. (2020). Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia. BMJ Open Gastroenterol., 7, No. 1, e000368. https://doi.org/10.1136/bmjgast-2019-000368
10. Jesch, E. D. & Carr, T. P. (2017). Food ingredients that inhibit cholesterol absorption. Prev. Nutr. Food Sci., 22, No. 2, pp.67-80. https://doi.org/10.3746/pnf.2017.22.2.67
11. Zhang, P., Chen, Y., Cheng, Y., Hertervig, E., Ohlsson, L., Nilsson, A. & Duan, R.-D. (2014). Alkaline sphingomyelinase (NPP7) promotes cholesterol absorption by affecting  sphingomyelin levels in the gut: A study with NPP7 knockout mice. Am. J. Physiol. Gastrointest. Liver Physiol., 306, No. 10, pp. G903-G908. https://doi.org/10.1152/ajpgi.00319.2013
12. Gryshchenko, V., Danchenko, O. & Musiychuk, V. (2019). Modification of modeling methodof toxic dystrophy of liver in rats. In Nadykto, V. (Eds). Modern development paths of agricultural production (pp. 689- 697). Cham: Springer. https://doi.org/10.1007/978-3-030-14918-5_67
13. Pаt. 86516 UA, ICP 61К 35/20, А23К 1/00. Veterinary bioactive addidition of liposomal form and method of reparative therapy in hepatology, Melnychuk, D. O.,  Gryshchenko, V. A. & Lytvynenko, O. M., Publ. 27.04.2009 (in Ukrainian).
14. Pat. 99031324 UA, IPC А61В5/14, Method of preparation of samples of bioridines to determine the content of substances of lipid nature, Vesel’s’kyy, S. P., Lyashchenko, P. S., Kostenko, S. I., Horenko, Z. A. & Ku rovs’ka, L. F., Publ. 15.02.2001 (in Ukrainian).
15. Schulze, R. J., Micah, B., Schott, M. B., Carol, A., Casey, C. A., Pamela, L., Tuma, P. L., Mark, A. & McNiven, M. A. (2019). The cell biology of the hepatocyte: A membrane trafficking machine. J. Cell Biol., 218, No. 7, pp. 2096-2112. https://doi.org/10.1083/jcb.201903090